Broker research reports for stocks which have been upgraded by brokers. Both recommendation upgrades,
as well as share price target upgrades are available .
Broker Research reports: latest Upgrades
for all stocks
During Q4FY25, the Net Interest Income stood at INR 27,559 Mn., down 3.6% YoY (-2.1% QoQ), below our estimates by 3.7% driven by higher slippages, and lower interest income led by increasing share of secured loans (now stands at ~50% of the book). Core NIMs stood at 6.7%, contracting by 90 bps YoY (-20 bps QoQ).
Epigral posted in-line results, with revenue/EBITDA/PAT up 20%/12%/12% YoY. This was largely led by improvement in ECUs in the caustic soda business and higher realizations for ECH (because of ADD), volume growth in the derivatives and specialty segment (CPVC, ECH).
Q4FY2025 Consolidated revenue of Rs. 4,988 crore (up 27.5%y-o-y) was ahead of our estimates. Revenues increased due to strong volume growth in the fertilizer and the crop protection business.
Consolidated revenues for Q4FY25 stood at INR 3,65,952 Mn., reflecting a growth of 14.2% YoY (+14.2% QoQ), surpassing our estimates led by higher revenue from operations and higher premium income. Consolidated profit stood at INR 47,563 Mn., up 16.4% YoY (+7.8% QoQ). The cost-to-income ratio improved to 72.5% from 74.6% in Q4FY24. Net income was largely in-line with our estimates.
Net Interest Income for Q4FY25 stood at INR 72,836 Mn., up 5.4% YoY (+1.2% QoQ), below our estimates by 1.2% led by lower-than-expected growth in advances. PPOP came in at INR 54,722 Mn., up 0.2% YoY (+5.7% QoQ). Adjusted PAT stood at INR 35,517 Mn., down 14.1% YoY (+7.5% QoQ), in-line with our estimates, despite the provisions being higher (~30%) than our estimate led by lower taxes.
ACC reported strong topline performance for Q4FY25, revenue at INR 60,665 Mn, up 12.2% YoY (+14.7% QoQ), which was above our estimates by 16.7%, driven by sharp uptick in volume growth at 14.4% YoY (+11.2% QoQ) and higher premium product mix.
NII for Q4FY25 grew 22.4% YoY (+4.5% QoQ) to INR 98,072 Mn., which was below our estimates by 3.4%. PPOP stood at INR 79,675 Mn., up 24.3% YoY (+2.1% QoQ), which was below our estimates by 6.0%, led by weaker NII growth and higher other opex. PAT stood at INR 45,456 Mn., up 18.9% YoY (+5.5% QoQ), below our estimates led by higher provisions.
Net Interest Income (NII) for Q4FY25 increased by 2.7% YoY (+3.2% QoQ) to INR 4,27,746 Mn, in-line with our estimates. PPOP grew by 8.8% YoY (+32.8% QoQ) to INR 3,12,860 Mn., 16.2% above our estimates driven by supported by ~2x QoQ growth in non-interest income.
Indian Bank (INBK) reported a 4QFY25 PAT of INR29.6b (up 31.6% YoY/ 3.6% QoQ; 4% beat), driven by lower provisions and higher other income. NII grew 6.2% YoY/flat QoQ (in line) at INR63.9b. NIM dipped 8bp QoQ to 3.37% during the quarter.
IOCL’s 4QFY25 EBITDA was a 110% beat on est., driven by higher-thanestimated GRM (USD8/bbl) as well as marketing margins (INR5.9/lit). With tax rate coming in below est., resultant PAT stood 5x above est. at INR72.6b.
Kotak Mahindra Bank (KMB) reported a standalone 4QFY25 PAT of ~INR35.5b (6% miss on MOFSLe), because of higher provisions (to shore up PCR, partly due to AIF provisions of INR560m). Consol. PAT stood at INR49b (5% QoQ growth and 8% YoY decline) in 4QFY25.
